Tapering JAK Inhibitor Doses in Rheumatoid Arthritis Patients
Compares lowering JAK inhibitor doses with continuing full doses in people with rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: JAK Inhibitor Dose TAPering Strategy Study
Key facts
- Where
- Amiens Cedex 1, Bordeaux, Brest Cedex 2, Chambray Les Tours, Clermont Ferrand Cedex 1, Le Kremlin-Bicetre, Le Mans Cedex 9, Limoges, Lomme Cedex, Marseille, Montpellier Cedex 5, Nice, Orleans Cedex 2, Paris, Paris Cedex 10, Paris Cedex 13, Paris Cedex 14, Reims, Rouen Cedex, Saint-Priest-en-Jarez, Strasbourg Cedex 2, Toulouse, and Vandoeuvre Les Nancy Cedex, FranceSee the 23 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06687551, who can take part
Where in France
- Centre Hospitalier Universitaire Amiens PicardieAmiens Cedex 1, FranceTaking people
- Centre hospitalier Universitaire de BordeauxBordeaux, FranceTaking people
- Centre Hospitalier Regional Et Universitaire De BrestBrest Cedex 2, FranceTaking people
- Centre Hospitalier Regional Universitaire De ToursChambray Les Tours, FranceTaking people
- University Hospital Of Clermont-FerrandClermont Ferrand Cedex 1, FranceTaking people
- Assistance Publique Hopitaux De ParisLe Kremlin-Bicetre, FranceTaking people
- Centre Hospitalier Le MansLe Mans Cedex 9, FranceTaking people
- Centre Hospitalier Et Universitaire de LimogesLimoges, FranceTaking people
- Groupement Des Hopitaux De L'Institut Catholique De LilleLomme Cedex, FranceTaking people
- Assistance Publique Hôpitaux de MarseilleMarseille, FranceTaking people
- Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranceTaking people
- Centre Hospitalier Universitaire de NiceNice, FranceTaking people
- Centre Hospitalier Regional D'orleansOrleans Cedex 2, FranceTaking people
- Assistance Publique Hopitaux de ParisParis, FranceTaking people
- Assistance Publique Hopitaux De ParisParis Cedex 10, FranceTaking people
- Assistance Publique Hopitaux De ParisParis Cedex 13, FranceTaking people
- GIE Groupe hospitalier Paris Saint-Joseph/VinciParis Cedex 14, FranceTaking people
- Centre Hospitalier Universitaire ReimsReims, FranceTaking people
- CHU De RouenRouen Cedex, FranceTaking people
- Centre Hospitalier Universitaire de Saint EtienneSaint-Priest-en-Jarez, FranceTaking people
- Les Hopitaux Universitaires De StrasbourgStrasbourg Cedex 2, FranceTaking people
- Centre Hospitalier Universitaire de ToulouseToulouse, FranceTaking people
- CHRU De NancyVandoeuvre Les Nancy Cedex, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Toulouse
- Trial code
- NCT06687551EU 2023-509788-25-00
- Record updated
- 7 August 2026
- Original description
This study aims to assess the feasibility of tapering JAK inhibitors in rheumatoid arthritis patients in low disease activity by comparing a group of patients tapering the JAK inhibitor dosage to a group of patients continuing the full-dose.Read full original descriptionShow less
JAK Inhibitor Dose TAPering Strategy Study in Low Disease Activity Rheumatoid Arthritis Patients
This study aims to assess the feasibility of tapering JAK inhibitors in rheumatoid arthritis patients in low disease activity by comparing a group of patients tapering the JAK inhibitor dosage to a group of patients continuing the full-dose.
Participants will:
* Either take
1. JAK inhibitor dose-tapering strategy. 2. JAK inhibitor continuous therapy strategy. * Visit the clinic once every 3 months for checkups and tests * Keep a diary of their treatment intake and symptoms
The inclusion criteria will be; Aged ≥ 18 years at baseline; Rheumatoid arthritis defined by the ACR/EULAR criteria; Treated with a JAK inhibitor, full dose for at least 6 months; The JAK inhibitor is prescribed as monotherapy or combined with a csDMARD with a stable dosage for at least 3 months before inclusion; Being in LDA (CDAI≤10) for at least 6 months; With a CRP level below the laboratory standard within the month before the inclusion visit; Women of childbearing potential (WCBP) must have a negative pregnancy test before starting study; The non-inclusion criteria will be:; Concomitant disease needing to be treated by the JAK inhibitor at full-dose (for example inflammatory bowel disease); Patient with a history of JAK-inhibitor dose reduction/spacing before enrollment in the study with the JAK-inhibitor currently being taken; Evidence of flare-up within the last 6 months prior to the inclusion; Patient who received glucocorticoids > 5mg/day in the 3 months prior the inclusion because of the disease activity of the RA; Patient requiring corticoid joint injections in the 3 months prior to inclusion or with scheduled joint injections, to control disease activity; Patient at risk for complication according to the ANSM (60) (current or past smokers, patients at risk of VTE, cancer or major cardiovascular problems, aged ≥ 65 years) at baseline AND currently taking baricitinib or filgotinib; Patient taking associated bDMARD (including anti-TNF, anti-IL6, anti-CD20, abatacept, anti-IL17, anti-IL12/23, anti-IL23, anti-IL1, anti-BAFF, anti-IL5 pathways); Patient taking immunotherapy for neoplasia; Surgery scheduled in the next 12 months; Fibromyalgia according to the physician's opinion; Anticipated poor compliance with the strategy; Patient with any condition that would prevent participation in the study and completion of the study procedures, including language limitation; Alcohol and/or drug misuse as determined by the investigator; Pregnancy or breastfeeding; Non-affiliation to the French Social Security System; Patient unwilling to sign the informed consent form; Patient under legal protection.